ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

Scientific Process

September 25, 1998

What? Only a “B”? NLST Co-Principal Investigator Begs to Differ with USPSTF Lung Cancer Screening Grade

August 9, 2013

Gene Delivery System Targets Tumor Blood Vessels In Dogs

March 27, 2009

Funding Opportunities: NCI Offers Funds To Develop, Validate Mouse Models

November 20, 1998

House, Senate Committee Increase FDA Funding, Drop User Fees

August 4, 1989

In Congress: NCI Apologizes For Delay In Report On Radioactive Fallout

September 18, 1998